Seven Eight Capital’s Biogen BIIB Stock Holding History

Seven Eight Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,724	Closed	-$372K	–	702
2024 Q1	$372K	Buy	+1,724	New	+$404K	0.04%	500
2021 Q2	–	Sell	-3,760	Closed	-$921K	–	585
2021 Q1	$921K	Hold	3,760	–	–	0.21%	176
2020 Q4	$921K	Buy	+3,760	New	+$970K	0.21%	178
2020 Q1	–	Sell	-9,326	Closed	-$2.77M	–	472
2019 Q4	$2.77M	Sell	9,326 -32,000	-77%	-$8.88M	0.15%	212
2019 Q3	$9.62M	Sell	41,326 -31,674	-43%	-$7.38M	0.51%	46
2019 Q2	$17.1M	Buy	+73,000	New	+$16.9M	0.9%	9
2018 Q2	–	Sell	-2,800	Closed	-$767K	–	468
2018 Q1	$767K	Buy	+2,800	New	+$869K	0.06%	240
2017 Q3	–	Sell	-4,900	Closed	-$1.33M	–	452
2017 Q2	$1.33M	Buy	4,900 +3,400	+227%	+$899K	0.19%	170
2017 Q1	$410K	Sell	1,500 -2,400	-62%	-$679K	0.08%	289
2016 Q4	$1.11M	Buy	+3,900	New	+$1.16M	0.22%	169

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seven Eight Capital's BIIB Position: Q2 2024 in Review

Seven Eight Capital sold out of Biogen (BIIB) in Q2 2024, closing a stake of 1,724 shares — an estimated $372K sold.

Seven Eight Capital first reported a position in BIIB in Q4 2016 and held it in 10 quarters. The position peaked at $17.1M in Q2 2019. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Seven Eight Capital reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Seven Eight Capital sold 1,724 Biogen shares in Q2 2024, an estimated $372K.
Seven Eight Capital first reported a position in Biogen in Q4 2016 and held it in 10 quarters.
Seven Eight Capital's Biogen position peaked at $17.1M in Q2 2019.
944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.